KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior
- 1 July 2017
- journal article
- Published by Elsevier in Human Pathology
- Vol. 65, 21-30
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysisActa Oncologica, 2014
- Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized MedicinePLOS ONE, 2013
- Colorectal Cancers from Distinct Ancestral Populations Show Variations in BRAF Mutation FrequencyPLOS ONE, 2013
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerNew England Journal of Medicine, 2013
- Tumor budding in colorectal carcinoma: time to take noticeLaboratory Investigation, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysisRadiology and Oncology, 2011
- Targeted treatments in colorectal cancer: state of the art and future perspectivesGut, 2010
- Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colonNature Genetics, 2008
- A New Prognostic Staging System for Rectal CancerAnnals of Surgery, 2004